Legend Biotech Corp. (LEGN)
20.94
-0.88
(-4.03%)
USD |
NASDAQ |
Aug 24, 16:00
21.31
+0.37
(+1.77%)
After-Hours: 20:00
Legend Biotech Debt to Equity Ratio : 0.2263 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.2263 |
| March 31, 2026 | 0.4023 |
| December 31, 2025 | 0.4128 |
| September 30, 2025 | 0.4057 |
| June 30, 2025 | 0.3746 |
| March 31, 2025 | 0.3565 |
| December 31, 2024 | 0.3369 |
| September 30, 2024 | 0.3105 |
| June 30, 2024 | 0.2924 |
| March 31, 2024 | 0.2875 |
| December 31, 2023 | 0.2626 |
| September 30, 2023 | 0.2393 |
| June 30, 2023 | 0.2264 |
| March 31, 2023 | 0.4819 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.3823 |
| September 30, 2022 | |
| June 30, 2022 | 0.3479 |
| March 31, 2022 | 0.1783 |
| December 31, 2021 | 0.1605 |
| September 30, 2021 | 0.3255 |
| June 30, 2021 | 0.0592 |
| March 31, 2021 | 0.0152 |
| December 31, 2020 | 0.0062 |
| September 30, 2020 | 0.0119 |
| June 30, 2020 | 0.0086 |
| March 31, 2020 | -0.9331 |
| December 31, 2019 | -0.0495 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| AbbVie, Inc. | -11.93 |
| Dianthus Therapeutics, Inc. | 0.0011 |
| Gilead Sciences, Inc. | 2.219 |
| Ironwood Pharmaceuticals, Inc. | -2.452 |
| Arbutus Biopharma Corp. | 0.014 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.751B |
| Total Liabilities (Quarterly) | 521.32M |
| Shareholders Equity (Quarterly) | 1.230B |
| Current Ratio | 3.041 |
| Net Debt Paydown Yield | 0.30% |